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Introduction:  This  analysis  was  conducted  to  assess  the  tolerability,  safety,  and  efﬁcacy  of brivaracetam
(BRV)  for  adjunctive  treatment  of focal  (partial-onset)  seizures  in  patients  aged  ≥65  years.
Methods:  Safety/tolerability  and  efﬁcacy  data  for patients  aged  ≥65  years  were  pooled  from  three  ran-
domized,  double-blind,  placebo-controlled,  ﬁxed-dose  Phase  III studies  (NCT00490035,  NCT00464269,
and  NCT01261325).  Data  were pooled  by  treatment  group:  placebo  or  the  proposed  therapeutic  dose
range  of  50–200  mg/day:  BRV  50,  100,  200  mg/day.
Results:  Thirty-two  patients  aged  ≥65  years  were  randomized  to  placebo  or  BRV  50–200  mg/day.  Of  these,
30  patients  (93.8%)  completed  their  respective  study.  In the  safety  population  (n =  32), 87.5%  placebo-  vs
73.3% BRV-treated  patients  reported  treatment-emergent  adverse  events  (TEAEs)  during  the  treatment
period;  most  commonly,  headache  (25.0%  vs  12.5%),  paresthesia  (0% vs  12.5%),  and somnolence  (50.0%
vs  12.5%)  for  placebo-  vs  BRV-treated  patients,  respectively.  During  the  treatment  period,  drug-related
TEAEs  were  reported  by 62.5%  of  placebo-  vs  53.3%  of BRV-treated  patients,  and  serious  TEAEs  (SAEs)
were  reported  by 0%  of placebo-  and  4.2%  of  BRV-treated  patients;  there  were  no drug-related  SAEs  and
no deaths.  Three  SAEs  (placebo  1/8;  BRV  2/24)  and  two  deaths  (placebo  1/8;  BRV  1/24)  occurred  in  the
post-treatment  period.  In the  efﬁcacy  population  (n = 31),  median  percent  reduction  from  baseline  in
focal  seizure  frequency/28  days  was  14.0%  for placebo  vs  25.5%,  49.6%,  and  74.9%  for  BRV 50,  100,  and
200  mg/day,  respectively.  The  ≥50%  responder  rate was  14.3%  for placebo  vs  25.0%,  50.0%,  and  66.7%  for
BRV  50,  100,  and  200  mg/day,  respectively.
Conclusions:  Safety/tolerability  and  efﬁcacy  ﬁndings  in this  small  subgroup  of  older  patients  treated  with
adjunctive  BRV  are  consistent  with  those  observed  in  the much  larger overall  pooled  population.  BRV
may  be a suitable  adjunctive  treatment  for older  patients  with  uncontrolled  focal  seizures.  Further  larger
studies in this  population  are  warranted.
ublis© 2016  The  Authors.  P
. IntroductionEpilepsy is common in older adults; causes of new-onset
pilepsy at older ages include cerebrovascular disease, dementia,
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Alzheimer’s, brain tumor, primary neurodegenerative disorders,
and traumatic head injury (Brodie et al., 2009; Pugh et al., 2009).
The incidence of treated epilepsy has been estimated at 80.8 per
100,000 in the general population, rising to 85.9 per 100,000 in
those aged 65–69 years, and 135.4 per 100,000 in people ≥85 years
(Wallace et al., 1998). In addition to older patients with new-onset
epilepsy, the population of older adults with epilepsy also includes
those who  have been treated for many decades.
The mortality rates for people diagnosed with epilepsy are 3.1,
1.7, and 2.0 times greater than the general population for those aged
60–69, 70–79, and ≥80 years (Lhatoo et al., 2001). Age-associated
effects on antiepileptic drug (AED) pharmacokinetics (PK) and
pharmacodynamics mean that AED selection and dosages may  need
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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djustment in this population (Turnheim, 2003). Older patients
re often receiving concomitant drugs for multiple comorbidities.
herefore, enzyme induction by some AEDs poses a particular chal-
enge for optimal polypharmacy in older patients (Brodie et al.,
013; Perucca, 2006).
There are relatively few randomized controlled trials of AEDs
n older populations. The evidence base currently supports the use
f lamotrigine or levetiracetam (LEV) as a ﬁrst-line AED in older
atients with epilepsy (Brodie et al., 1999; Rowan et al., 2005;
aetre et al., 2007; Werhahn et al., 2015).
Brivaracetam (BRV), a selective, high-afﬁnity synaptic vesicle
rotein 2A ligand, has been approved by the USA, Canada, and
urope as adjunctive therapy for focal seizures in adults (≥16 years)
ith epilepsy. A study in 16 older healthy volunteers found that BRV
as well tolerated, with adverse events comparable to a younger
opulation (Sargentini-Maier et al., 2009). The objective of the cur-
ent analysis was to assess the tolerability, safety, and efﬁcacy of
RV for adjunctive treatment of focal seizures in older patients. This
rticle reports a post-hoc analysis of pooled data from three pivotal
tudies which enrolled patients aged ≥65 years (Biton et al., 2014;
lein et al., 2015; Ryvlin et al., 2014).
. Methods
.1. Study designs
The methodology and study designs have been published for the
hree randomized, double-blind, placebo-controlled, ﬁxed-dose
hase III studies used in this analysis (Biton et al., 2014; Klein et al.,
015; Ryvlin et al., 2014). After an 8-week prospective baseline
eriod, patients received placebo or BRV (5–200 mg/day), initiated
ithout up-titration for a 12-week treatment period. The stud-
es were conducted in accordance with accepted guidelines and
ll patients provided written informed consent before study enrol-
ent.
.2. Participants
The three studies enrolled patients with focal seizures, with
r without secondary generalization, uncontrolled on 1–2 AEDs.
tudies NCT00490035 and NCT00464269 included adults aged
6–70 years ≥45 kg. Study NCT01261325 included adults aged
6–80 years ≥40 kg. Patients were required to have ≥2 focal
eizures/month during the 3 months before baseline, and ≥8 focal
eizures during the 8-week baseline period (with ≥2 focal seizures
uring each 4-week period in study NCT01261325). In two stud-
es, concomitant LEV was limited to 20% of the population; in study
CT01261325 concomitant LEV was not allowed.
.3. Endpoints and statistical analysis
Tolerability and safety endpoints were treatment-emergent
dverse events (TEAEs), laboratory assessments, vital signs, and
lectrocardiograms (ECGs) during the treatment period. Efﬁcacy
ndpoints included median percent reduction in focal seizure
requency from baseline/28 days, ≥50% responder rate (≥50%
eduction in focal seizure frequency from baseline), and seizure
reedom rate (all seizure types) during the treatment period.
Data from the three studies were pooled; further details are pre-
ented elsewhere (Ben-Menachem et al., 2016). Data were pooled
y treatment group for the approved dose range of 50–200 mg/day:
RV 50, 100, 200 mg/day or placebo. This post-hoc analysis included
atients aged ≥65 years.
The safety population comprised patients taking ≥1 dose of
tudy drug. The efﬁcacy population comprised patients from the
rimary efﬁcacy analyses: the intent-to-treat (ITT) population inrch 127 (2016) 114–118 115
studies NCT00490035 and NCT01261325, and the modiﬁed ITT
population in study NCT00464269, who  were not receiving LEV at
study entry.
3. Results
3.1. Patient disposition
Overall, 1558 patients were randomized, of whom 38 were aged
≥65 years. Of these, 32 patients were randomized to placebo (n = 8)
or BRV 50–200 mg/day (n = 24) and are included in the safety pop-
ulation of this analysis. In total, 30/32 patients (93.8%) completed
their respective studies; 2/32 (6.3%) discontinued due to adverse
events.
3.2. Patient demographics and baseline characteristics
At baseline, patients ≥65 years had a mean (standard deviation
[SD]) age of 72.1 (4.2) years vs 69.3 (3.6) years, and 57.1% and 54.2%
were male, in the placebo and BRV groups, respectively. Patients
had a long duration of epilepsy (mean [SD] duration: 24.8 [14.7]
vs 34.1 [20.6] years), and median focal seizure frequency/28 days
at baseline was  9.6 vs 7.5, for the placebo and BRV groups, respec-
tively. Most patients had discontinued ≥2 prior AEDs; more than
half had previously discontinued LEV. The most common concomi-
tant AEDs were oxcarbazepine, carbamazepine, lamotrigine, and
lacosamide (Table 1).
3.3. Safety and tolerability
In patients aged ≥65 years (n = 32), mean (SD) drug exposure
was 81.1 (12.0) days for placebo and 82.6 (18.0) days for BRV.
Altogether, 7/8 (87.5%) placebo vs 16/24 (66.7%) BRV patients
reported TEAEs during the treatment period (Table 2). Of these,
5/8 (62.5%) placebo vs 13/24 (54.2%) BRV patients reported drug-
related TEAEs. Few patients discontinued study drug due to TEAEs:
1/8 (12.5%) patients on placebo and 1/24 (4.2%) patients on
100 mg/day BRV. The most commonly reported TEAEs were
headache (placebo 2/8; 25.0% vs BRV 3/24; 12.5%), paresthesia (0/8;
0% vs 3/24; 12.5%), and somnolence (4/8; 50.0% vs 3/24; 12.5%)
(Table 2).
During the treatment period, serious TEAEs (SAEs) were
reported by no placebo patients and one BRV-treated patient (a
76-year-old woman  receiving BRV 100 mg/day fell after a seizure
resulting in hematoma, kidney injury, and a broken rib; BRV was
permanently discontinued). No drug-related SAEs or deaths were
reported during the treatment period.
After core study completion, SAEs were reported by one
placebo- and two  BRV-treated patients. A 70-year-old woman
receiving BRV during long-term follow-up fractured her pelvis
in an accidental fall (considered unrelated to study drug), which
resolved. A 68-year-old man  previously receiving placebo died from
septicemia and a 70-year-old man  previously receiving BRV 100
mg/day had a septic infection (after 8 days the patient went into
septic shock, BRV was withdrawn, and after 3 weeks the patient
died). Both deaths were thought unlikely related to study drug.
Patient numbers were small; however, there were no trends of
clinical concern in the laboratory assessments.
3.4. Efﬁcacy
In patients aged ≥65 years (n = 31), median percent reduc-
tion from baseline in focal seizure frequency/28 days was 14.0%
(placebo) vs 25.5%, 49.6%, and 74.9% (BRV 50, 100, and 200 mg/day,
respectively) (Fig. 1A). Similarly, the ≥50% responder rate was  1/7
(14.3%) for placebo vs 1/4 (25.0%), 7/14 (50.0%), and 4/6 (66.7%)
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Table 1
Patient demographics and baseline characteristics in patients aged ≥65 years (n = 31).
Placebo
(n = 7)
BRV 50 mg/day
(n = 4)
BRV
100 mg/day
(n = 14)
BRV
200 mg/day
(n = 6)
BRV overall
(n = 24)
Mean (SD) age,
years
72.1 (4.1) 68.8 (1.9) 70.0 (4.1) 67.8 (3.2) 69.3 (3.6)
Male  gender, n (%) 4 (57.1) 1 (25.0) 9 (64.3) 3 (50.0) 13 (54.2)
Mean  BMI  (SD),
kg/m2
24.8 (5.3) 27.4 (2.8) 27.9 (4.0) 28.0 (4.2) 27.8 (3.7)
Race,  n (%)
White
Asian
Othera
5 (71.4)
1 (14.3)
1 (14.3)
4 (100.0)
0
0
14 (100.0)
0
0
6 (100.0)
0
0
24 (100.0)
0
0
Etiology, n (%)
Idiopathic
Symptomatic
Cryptogenic
Unknown
2 (28.6)
2 (28.6)
3 (42.9)
0b
0
3 (75.0)
1  (25.0)
0
2 (14.3)
5 (35.7)
7 (50.0)
0
1 (16.7)
3  (50.0)
2  (33.3)
0
3 (12.5)
11 (45.8)
10 (41.7)
0
Mean (SD) [range]
duration of
epilepsy, years
24.8 (14.7)
[3–48]
45.9 (13.0)
[28–58]
27.2 (17.6)
[3–53]
42.2 (26.8)
[2–69]
34.1 (20.6)
[2–69]
Median
(minimum–maximum)
focal  seizure fre-
quency/28 days
at baseline
9.6 (6, 71) 15.4 (4, 37) 6.8 (4, 17) 7.5 (4, 12) 7.5 (4, 37)
Number of prior AEDs, n (%)
0–1
2–4
≥5
1 (14.3)
3 (42.9)
3 (42.9)
0
4 (100.0)
0
3 (21.4)
5 (35.7)
6 (42.9)
1 (16.7)
2  (33.3)
3  (50.0)
4 (16.7)
11 (45.8)
9 (37.5)
Prior  LEV
treatment, n (%)
4 (57.1) 3 (75.0) 7 (50.0) 4 (66.7) 14 (58.3)
Concomitant AEDsb, n (%)
Oxcarbazepine
Carbamazepine
Lamotrigine
Lacosamide
0
1 (14.3)
1 (14.3)
1 (14.3)
1 (25.0)
3  (75.0)
0
0
6 (42.9)
2 (14.3)
2 (14.3)
1 (7.1)
1 (16.7)
1  (16.7)
1  (16.7)
2  (33.3)
8 (33.3)
6 (25.0)
3 (12.5)
3 (12.5)
Note: The efﬁcacy population comprised all patients from the primary efﬁcacy analyses in studies N01252, N01253, and N01358, excluding patients receiving concomitant
LEV  in studies N01252 and N01253. AED, antiepileptic drug; BMI, body mass index; BRV, brivaracetam; LEV, levetiracetam; SD, standard deviation.
a Other race includes black, other, and missing.
b ≥10% in BRV overall group.
Table 2
Summary of TEAEs and most commonly reported TEAEs during the treatment period (n = 32).
Patients, n (%) Placebo
(n = 8)
BRV 50 mg/day
(n = 4)
BRV
100 mg/day
(n = 14)
BRV
200 mg/day
(n = 6)
BRV overall
(n = 24)
≥1 TEAE 7 (87.5) 3 (75.0) 9 (64.3) 4 (66.7) 16 (66.7)
TEAEs  leading to
discontinuation of
study drug
0 0 1 (7.1) 0 1 (4.2)
Drug-related TEAEs 5 (62.5) 3 (75.0) 6 (42.9) 4 (66.7) 13 (54.2)
SAEs  0 0 1 (7.1) 0 1 (4.2)
Drug-related SAEs 0 0 0 0 0
Deaths 0 0 0 0 0
TEAEs  reported by ≥5% patients in the overall BRV group, n (%)
Headache 2 (25.0) 1 (25.0) 1 (7.1) 1 (16.7) 3 (12.5)
Paresthesia 0 1 (25.0) 2 (14.3) 0 3 (12.5)
Somnolence 4 (50.0) 0 2 (14.3) 1 (16.7) 3 (12.5)
Cataract 0 1 (25.0) 1 (7.1) 0 2 (8.3)
Constipation 0 0 2 (14.3) 0 2 (8.3)
Convulsion 0 0 2 (14.3) 0 2 (8.3)
Cystitis 0 0 2 (14.3) 0 2 (8.3)
Hyponatremia 0 0 1 (7.1) 1 (16.7) 2 (8.3)
Note: The safety population comprised all patients randomized to placebo or BRV dosages of ≥50 mg/day, who  received ≥1 dose of BRV, regardless of any concomitant
treatment with LEV. BRV, brivaracetam; LEV, levetiracetam; SAE, serious treatment-emergent adverse event; TEAE, treatment-emergent adverse event.
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hig. 1. (A) Median percent reduction from baseline in focal seizure frequency/28 d
n  = 31).
RV, brivaracetam; Q, quartile.
or BRV 50, 100, and 200 mg/day, respectively (Fig. 1B). Efﬁcacy
ppeared to increase with increased BRV dosage, although the
atient numbers were small. The number of patients continuously
ree of seizures (all seizure types) were 0/7 (placebo) vs 3/24 BRV
1/4, 1/14, and 1/6 patients for BRV 50, 100, and 200 mg/day, respec-
ively).
. Discussion and conclusions
In this small subgroup of older patients treated with adjunctive
RV, a comprehensive evaluation of TEAEs and laboratory assess-
ents did not reveal any issues of clinical concern. Seizure control
ates were higher with BRV than placebo and compared favorably
ith those observed in the much larger overall pooled popula-
ion (Ben-Menachem et al., 2016). Indeed, seizure reduction rates
ere higher than for the overall population. It should be noted
hat the population analyzed here had a long epilepsy duration and
he majority had received ≥2 prior AEDs; they were therefore not
ypical of patients with new-onset epilepsy at older ages.
BRV has several characteristics which make it a potentially
avorable choice for older patients, although appropriate caution
hould be taken for this population; a lower dose may  be necessary
or patients with decreased hepatic, renal, or cardiac function. BRV
as a low potential to induce or inhibit the cytochrome (CYP) sys-nd (B) ≥50% responder rate for focal seizure frequency, in the efﬁcacy population
tem (Chanteux et al., 2015), except for CYP2C19 which is involved in
secondary metabolism of BRV (Sargentini-Maier et al., 2008). It acts
as a moderate inhibitor of epoxide hydrolase (Stockis et al., 2015).
In the pivotal trials, BRV showed a favorable safety and tolerability
proﬁle and titration was  not required for tolerability reasons (Biton
et al., 2014; Klein et al., 2015; Ryvlin et al., 2014).
Limitations of this analysis include its post-hoc nature and the
small number of patients aged ≥65 years. A higher age cut-off or
further age stratiﬁcations might be useful in future studies, as might
studies in patients with late-onset epilepsy.
Based on these results, BRV may  be a suitable adjunctive treat-
ment for older patients with uncontrolled focal seizures. The
tolerability and safety proﬁle was similar to, and efﬁcacy rates were
higher than, the overall pooled population. However, owing to the
small number of patients in this analysis, further studies in older
patients are warranted.
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